Site-specific drug release of monomethyl fumarate to treat oxidative stress disorders
Nature Biotechnology · 2025-10 · 43 (10) · 1624-1627
DOI: 10.1038/s41587-024-02460-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nature Biotechnology, online erschienen am 04.11.2024. Verfasst von Thomas D Avery und 17 weiteren Autor:innen. Beteiligte Einrichtung: ARC Centre of Excellence for Nanoscale BioPhotonics (CNBP), The University of Adelaide, Adelaide, South Australia, Australia. Hauptthemen laut MEDLINE: Oxidative Stress, Fumarates, Prodrugs, Chronic Pain. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS), NIMHD NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
Treatment of diseases of oxidative stress through activation of the antioxidant nuclear factor E2-related factor 2 (NRF2) is limited by systemic side effects. We chemically functionalize the NRF2 activator monomethyl fumarate to require Baeyer-Villiger oxidation for release of the active drug at sites of oxidative stress. This prodrug reverses chronic pain in mice with reduced side effects and could be applied to other disorders of oxidative stress.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- ARC Centre of Excellence for Nanoscale BioPhotonics (CNBP), The University of Adelaide, Adelaide, South Australia, Australia.
- Institute for Photonics and Advanced Sensing (IPAS), The University of Adelaide, Adelaide, South Australia, Australia.
- Department of Chemistry, The University of Adelaide, Adelaide, South Australia, Australia.
- Laboratories of Neuroimmunology, Department of Symptom Research, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- MD Anderson Pain Research Consortium, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Pharmaceutical Science, Texas Southern University, Houston, TX, USA.
Förderung
- U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS)
- NIMHD NIH HHS
- NINDS NIH HHS
- Department of Education and Training | Australian Research Council (ARC)
- U.S. Department of Health & Human Services | National Institutes of Health (NIH)
- Cancer Prevention and Research Institute of Texas (Cancer Prevention Research Institute of Texas)
Zitieren
APA
Avery, T. D., Li, J., Turner, D. J. L., Rasheed, M. S. U., Cherry, F. R., Stachura, D. L., Rivera-Escalera, F., Ruiz, D. M., Lacagnina, M. J., Gaffney, C. M., Aguilar, C., Yu, J., Wang, Y., Xie, H., Liang, D., Shepherd, A. J., Abell, A. D., & Grace, P. M. (2025). Site-specific drug release of monomethyl fumarate to treat oxidative stress disorders. Nature Biotechnology, 43(10), 1624-1627. https://doi.org/10.1038/s41587-024-02460-4
Vancouver
Avery TD, Li J, Turner DJL, Rasheed MSU, Cherry FR, Stachura DL, et al. Site-specific drug release of monomethyl fumarate to treat oxidative stress disorders. Nature Biotechnology. 2025;43(10):1624-1627. doi:10.1038/s41587-024-02460-4
BibTeX
@article{Avery2025,
author = {Avery, Thomas D and Li, Jiahe and Turner, Dion J L and Rasheed, Mohd S U and Cherry, Fisher R and Stachura, Damian L and Rivera-Escalera, Fátima and Ruiz, David M and Lacagnina, Michael J and Gaffney, Caitlyn M and Aguilar, Clarissa and Yu, Jingxian and Wang, Yang and Xie, Huan and Liang, Dong and Shepherd, Andrew J and Abell, Andrew D and Grace, Peter M},
title = {Site-specific drug release of monomethyl fumarate to treat oxidative stress disorders},
journal = {Nature Biotechnology},
year = {2025},
volume = {43},
number = {10},
pages = {1624--1627},
doi = {10.1038/s41587-024-02460-4}
}
EUVIMED